NEW YORK (GenomeWeb) – If alternative payment models are structured in a way that doesn't allow doctors the flexibility to prescribe and gather evidence on innovative drugs and tests, they could end up impeding access to molecularly targeted treatment strategies, warns a Personalized Medicine Coalition report.

Get the full story with

GenomeWeb Premium

Only $95 for the

first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.

Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.